ABUS
Arbutus BiopharmaยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
ABUS Profile
Arbutus Biopharma Corporation
A clinical-stage biopharmaceutical company that developing therapeutics for hepatitis B virus
Biological Technology
10/06/2005
11/15/2010
NASDAQ Stock Exchange
44
12-31
Common stock
701 Veterans Circle , Warminster, PA, 18974
--
Arbutus Biopharma Corporation was incorporated in British Columbia on October 6, 2005. The Company is a clinical-stage biopharmaceutical company that leverages its extensive virology expertise to identify and develop novel therapies with unique mechanisms of action that can potentially be combined to provide a functional cure for patients with chronic hepatitis B virus (HBV) infection. The Company's pipeline of proprietary compounds developed in-house includes an RNA therapy drug imdusiran (AB-729) and an oral PD-L1 inhibitor AB-101. Imdusiran has produced meaningful clinical data demonstrating the effects on surface antigen reduction and reawakening of HBV-specific immune responses.
